ATE344051T1 - Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren - Google Patents

Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren

Info

Publication number
ATE344051T1
ATE344051T1 AT95926645T AT95926645T ATE344051T1 AT E344051 T1 ATE344051 T1 AT E344051T1 AT 95926645 T AT95926645 T AT 95926645T AT 95926645 T AT95926645 T AT 95926645T AT E344051 T1 ATE344051 T1 AT E344051T1
Authority
AT
Austria
Prior art keywords
cell
heparinases
extracellular matrix
growth factors
heparan sulfate
Prior art date
Application number
AT95926645T
Other languages
English (en)
Inventor
Joseph Zimmermann
Israel Vlodavsky
D Clark Bennett
Pamela Danagher
Richard Broughton
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Application granted granted Critical
Publication of ATE344051T1 publication Critical patent/ATE344051T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Adornments (AREA)
AT95926645T 1994-07-08 1995-07-07 Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren ATE344051T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/273,109 US5997863A (en) 1994-07-08 1994-07-08 Attenuation of wound healing processes

Publications (1)

Publication Number Publication Date
ATE344051T1 true ATE344051T1 (de) 2006-11-15

Family

ID=23042598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926645T ATE344051T1 (de) 1994-07-08 1995-07-07 Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren

Country Status (9)

Country Link
US (1) US5997863A (de)
EP (1) EP0769961B1 (de)
JP (1) JP4152433B2 (de)
AT (1) ATE344051T1 (de)
AU (1) AU707007B2 (de)
CA (1) CA2194370C (de)
DE (1) DE69535282T2 (de)
ES (1) ES2279514T3 (de)
WO (1) WO1996001648A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703394B2 (en) * 1995-09-29 1999-03-25 Biomarin Pharmaceutical Inc. Use of heparinases to decrease inflammatory responses
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
GB2317182B (en) * 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
AU3006899A (en) * 1998-03-13 1999-09-27 Biomarin Pharmaceutical Inc. Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
EP1109919A2 (de) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000052178A1 (en) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
EP1231935B1 (de) * 1999-11-17 2008-11-12 BioMarin Pharmaceutical Inc. Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme
US6979563B1 (en) 1999-11-17 2005-12-27 Biomarin Enzymes, Inc. Attenuation of tumor growth, metastasis and angiogenesis
WO2001038399A1 (fr) * 1999-11-24 2001-05-31 Seikagaku Corporation Procede de traitement des maladies des tissus superficiels
EP1266013B1 (de) * 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii und deren verwendungen
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物
AU2002342613A1 (en) * 2001-05-09 2002-11-25 Geron Corporation Treatment for wounds
MXPA04001334A (es) * 2001-08-13 2004-05-05 Univ Florida Materiales y metodos para promover la reparacion de tejido nervioso.
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
EP1575548B1 (de) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DE60334220D1 (de) * 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
ATE508197T1 (de) * 2002-08-15 2011-05-15 Acorda Therapeutics Inc Chimärisches protein
DE60332958D1 (de) * 2002-11-04 2010-07-22 Ocean Nutrition Canada Ltd Mikrokapseln mit mehrfachen hüllen und verfahren zu deren herstellung
ES2616749T3 (es) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004241088B2 (en) 2003-05-16 2010-08-05 Acorda Therapeutics, Inc. Compositions and methods for the treatment of CNS injuries
WO2004108065A2 (en) * 2003-06-09 2004-12-16 Insight Biopharmaceuticals Ltd. Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
EP1737476A4 (de) * 2004-01-30 2009-07-22 Univ Emory Materialien und verfahren zur förderung von nervenregeneration
EP1737954A2 (de) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Rekombinante chondroitinase abc i und verwendungen davon
WO2005112986A2 (en) * 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
US7767420B2 (en) * 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US7691612B2 (en) 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
CA2643662A1 (en) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
KR20170042364A (ko) * 2006-06-05 2017-04-18 디에스엠 뉴트리셔널 프라덕츠 아게 개선된 쉘을 가지는 마이크로캡슐
JP5391069B2 (ja) 2006-10-10 2014-01-15 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を使用する組成物及び方法
EP2124905B1 (de) 2007-01-10 2016-09-07 DSM Nutritional Products AG Mikrokapseln enthaltend erbsenprotein
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
WO2013039244A1 (ja) * 2011-09-15 2013-03-21 生化学工業株式会社 骨格筋再生促進剤
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
CN109182321A (zh) * 2018-09-14 2019-01-11 深圳市长征生物科技有限公司 肝素黄杆菌肝素酶ⅰ的高效制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
JPH04503734A (ja) * 1988-12-01 1992-07-02 ボック、エドワード 脈動、浮遊状態で搬送、処理する改良された装置
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
JP3188691B2 (ja) * 1989-08-23 2001-07-16 ハダサ メディカル オーガナイゼーション ヘパラナーゼを含む創傷治癒用組成物
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5262325A (en) * 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5389539A (en) * 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
AU1176595A (en) * 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
CA2176934A1 (en) * 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase

Also Published As

Publication number Publication date
EP0769961B1 (de) 2006-11-02
WO1996001648A1 (en) 1996-01-25
AU707007B2 (en) 1999-07-01
JP4152433B2 (ja) 2008-09-17
AU3094995A (en) 1996-02-09
ES2279514T3 (es) 2007-08-16
DE69535282D1 (de) 2006-12-14
JPH10506609A (ja) 1998-06-30
EP0769961A1 (de) 1997-05-02
US5997863A (en) 1999-12-07
DE69535282T2 (de) 2007-05-24
CA2194370C (en) 2001-02-27
CA2194370A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
ATE344051T1 (de) Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren
US7056711B2 (en) Attenuation of fibroblast proliferation
FI841358A (fi) Biologiskt aktiv sammansaettning foer rening av avfallsvatten och avluft.
DE69636410D1 (de) Mutierte alpha-amylase
MX9806064A (es) Composicion de enzimas para disociacion de tejidos.
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
AU7042196A (en) Method for controlling the suppression of the neoplastic phenotype
Abraham et al. Direct enzyme transfer from lymphocytes corrects a lysosomal storage disease
ATE249225T1 (de) Mannose-6-phosphat enthaltendes mittel und dessen verwendung bei der behandlungfibrotischer erkrankungen
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
DE60040800D1 (de) Verminderung von angiogenese unter verwendung chondroitinsulfat abbauender enzyme
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
Funderburgh et al. Corneal glycosaminoglycan synthesis in long-term organ culture.
ZA200108241B (en) Production of pancreatic procarboxy-peptidase B, Isoforms and muteins thereof, and their use.
ATE289349T1 (de) Vorläufer von normalen neuralen epithelzellen
Kress et al. Altered serum α-d-mannosidase activity in mucolipidosis II and mucolipidosis III
FI963755A (fi) Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaavat yhdistelmä-DNA-tekniset virukset
AU5783800A (en) Dsp-3 dual-specificity phosphatase
AU1598297A (en) Method of inactivation of ras subfamily proteins and agents therefor
EP1839671A3 (de) Abschwächung der Fibroplastprofileration
IMANARI et al. Time-course experiment involving glycosaminoglycan synthesis by normal human dermal fibroblasts cultured in the presence of dibutyryl cyclic AMP and retinoic acid
BR9405658A (pt) Método para prever o crescimento ativo de bactérias aderidas a uma superfície
IT1284658B1 (it) Stimolatore dell'attivita' enzimatica in cellule batteriche
MX9706182A (es) Uso de acido hialuronico para el tratamiento de cistitis intersticial.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties